Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Torres-Manjon
Observed name:
S. Torres-Manjon
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia
Observed institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Duran i Reynals Hospital,
ProCure (United States)
ORCID:
0009-0008-9378-1067
Observed ORCID:
0009-0008-9378-1067
OpenAlex ID:
A5022276874
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
2019
·
Guillem Pascual-Pasto
, Miriam Bazan-Peregrino
, et al.
·
Science Translational Medicine
·
121
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022
·
Rocio Garcia-Carbonero
, Miriam Bazan-Peregrino
, et al.
·
Journal for ImmunoTherapy of Cancer
·
109
PDF
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11
2021
·
Ana Mato-Berciano
, Sara Morgado
, et al.
·
Journal of Controlled Release
·
30
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
·
Clinical Cancer Research
·
5
Table S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S11 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S10 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S7 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S8 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Supplementary Text 1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S2 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S2 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Table S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Data from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Figure S8 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026
·
Maria Jove
, Irene Braña
, et al.
Show more works
View as search
Works count:
29
Citation count:
265
H-index:
4
I10-index:
3
Year
Topic
Type